<DOC>
	<DOCNO>NCT00203021</DOCNO>
	<brief_summary>Patients schedule visit every 3 month ass Copaxone safety Multiple Sclerosis status .</brief_summary>
	<brief_title>CopaxoneÂ® Study Follow Patients From First Original Study Safety Effectiveness .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Patients must participate ( randomize ) Copaxone DoubleBlind placebo control study ( Protocol 019001 ) . Gender : Patients may male female . Women childbearing potential must practice acceptable method birth control . Patients must sign approve informed consent prior initiate study . Patients must psychologically physically stable participate trial judge investigator . Pregnancy lactation . Medical psychiatric condition affect patient 's ability give inform consent complete study . Inability selfadminister subcutaneous medication lack another responsible individual administer study preparation daily . Use Interferons , experimental MS therapy , previous immunosuppressive therapy cytotoxic chemotherapy ( azathioprine , cyclophosphamide , cyclosporine ) , total lymphoid irradiation within 30 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>